```
1
                         UNITED STATES DISTRICT COURT
 2
                       FOR THE DISTRICT OF NEW JERSEY
 3
 4
    HELSINN HEALTHCARE, S.A. and
    ROCHE PALO ALTO, LLC,
 5
                                       CIVIL ACTION NUMBER:
              Plaintiffs,
 6
                                             11-3962
               -vs-
 7
    DR. REDDY'S LABORATORIES, LTD.,
                                              TRIAL
    DR. REDDY'S LABORATORIES, INC.,
    TEVA PHARMACEUTICALS USA, INC.,
    and TEVA PHARMACEUTICAL
    INDUSTRIES, LTD.
10
              Defendants.
11
         Clarkson S. Fisher United States Courthouse
12
         402 East State Street
         Trenton, New Jersey 08608
13
         June 5, 2015
14
                        THE HONORABLE MARY L. COOPER
    BEFORE:
                        UNITED STATES DISTRICT JUDGE
15
16
17
18
19
20
21
22
23
    Certified as True and Correct as required by Title 28, U.S.C.,
    Section 753
24
    /S/ Regina A. Berenato-Tell, CCR, CRR, RMR, RPR
25
    /S/ Carol Farrell, CCR, CRR, RMR, CCP, RPR,
```



Dr. Reddy's Laboratories, Ltd., et al.

```
1
                         UNITED STATES DISTRICT COURT
 2
                       FOR THE DISTRICT OF NEW JERSEY
 3
 4
   HELSINN HEALTHCARE, S.A. and
   ROCHE PALO ALTO, LLC,
 5
                                       CIVIL ACTION NUMBER:
              Plaintiffs,
 6
                                             11-3962
               -vs-
 7
    DR. REDDY'S LABORATORIES, LTD.,
                                              TRIAL
   DR. REDDY'S LABORATORIES, INC.,
   TEVA PHARMACEUTICALS USA, INC.,
    and TEVA PHARMACEUTICAL
    INDUSTRIES, LTD.
10
              Defendants.
11
         Clarkson S. Fisher United States Courthouse
12
         402 East State Street
         Trenton, New Jersey 08608
13
         June 5, 2015
14
                        THE HONORABLE MARY L. COOPER
    BEFORE:
                        UNITED STATES DISTRICT JUDGE
15
16
17
18
19
20
21
22
23
    Certified as True and Correct as required by Title 28, U.S.C.,
    Section 753
24
    /S/ Regina A. Berenato-Tell, CCR, CRR, RMR, RPR
25
    /S/ Carol Farrell, CCR, CRR, RMR, CCP, RPR, RSA
```



_				
1	APPEARANCES:			
<i>2 3</i>	PAUL HASTINGS BY: JOSEPH O'MALLEY, ESQUIRE			
4	BY: CHARLES M. LIZZA, ESQUIRE			
5				
6				
7	BUDD LARNER BY: STUART D. SENDER, ESQUIRE			
8	MICHAEL H. IMBACUAN, ESQUIRE HUA HOWARD WANG, ESQUIRE			
9	CONSTANCE S. HUTTNER, ESQUIRE KENNETH E. CROWELL, ESQUIRE			
10	Attorneys for the Defendant, Dr. Reddy's Laboratories			
11	WINSTON & STRAWN BY: JOVIAL WONG, ESQUIRE			
12	GEORGE LOMBARDI, ESQUIRE JULIA MANO JOHNSON, ESQUIRE			
13	BRENDAN F. BARKER, ESQUIRE LITE DePALMA, GREENBERG, LLC			
14	BY: MAYRA V. TARANTINO, ESQUIRE Attorneys for the Defendant, Teva			
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
2 . 25				
20				



1	I N D E X			
2				
3				
<i>4</i> 5	WITNESS VOIR DIRE	DIRECT	CROSS REDIRECT RECROSS	
6	Lee Edwin Kirsch By Mr. Wong 5	18		
7	By O'Malley	10	92	
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18 19				
20				
21				
22				
23				
24				
25				

- 1 | eight asserted claims?
- $2 \mid A$. Yes. Claim 7 in the '219 patent really contains the
- 3 elements that are relevant.
- 4 Q. And we'll get to each of these elements in a bit, but
- 5 what is your general opinion regarding each of the components
- 6 listed here for Claim 7?
- 7 A. Well, it's my opinion that these elements are a
- 8 description or involve the description of a common -- commonly
- 9 used conditions and components in I.V. formulations that are
- 10 used for their common uses. So, in my opinion, this patent is
- 11 invalid because of obviousness.
- 12 Q. Now, have you considered who a person of ordinary skill
- 13 in the art would be with respect to the four patents?
- **14** | A. Yes, I have.
- 15 | Q. And who would that person be?
- $16 \mid A$. The person of ordinary skill in the art, a POSA, would be
- 17 a formulation scientist typically with a Ph.D. in
- 18 pharmaceutics or a related field and would have a couple of
- 19 | years of experience in developing I.V. formulations.
- 20 Q. Okay. Now, in your opinion, would this POSA have actual
- **21** experience preparing formulations at the bench?
- 22 A. Yes.
- 23 Q. And what is the scope of resources that a POSA would draw
- **24** upon when developing a formulation?
- 25 A. Well, a POSA would have their training and background,



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

